摘要
目的探讨头孢哌酮/舒巴坦治疗尿毒症患者肺部感染的疗效和安全性。方法将60例尿毒症合并肺部感染患者随机分为治疗组和对照组,各30例,治疗组给予静脉滴注头孢哌酮/舒巴坦和头孢哌酮,2次/d,对照组仅给予静脉滴注头孢哌酮,2次/d。对比治疗前、后两组的临床疗效变化。结果治疗组临床总有效率为83.3%,细菌清除率为92.86%;对照组临床总有效率为63.3%,细菌清除率为72.41%。治疗组疗效明显优于对照组。结论头孢哌酮/舒巴坦治疗尿毒症并发肺部感染的疗效优于头孢哌酮,不良反应无明显增加,安全性高。
Objective To explore the efficacy and safety of cefoperazone/sulbactam in treatment of uremic patients complicated by pulmonary infection.Methods 60 cases uremic patients with pulmonary infection were randomized into treatment group and control,30 cases in each group,treatment group was given cefoperazone/sulbactam and cefoperazone,the control group was only given cefoperazone,twice a day in the two groups.Results The efficiency rate of treatment group was83.3%,and the bacterial clearance rate was 92.86%;In control,the overall efficiency rate was 63.3%,the bacterial clearance rate was 72.41%,the curative effect of treatment group was better than control.Conclusion Cefoperazone/sulbactam is more efficient in the treatment of uremic patients with pulmonary infection than cefoperazone,which does not increase adverse reactions and has a high safety.
出处
《中国卫生产业》
2016年第6期55-57,192,共4页
China Health Industry
